Longbio
About Longbio
Longbio Pharma is a biotech startup focused on developing innovative therapies for autoimmune and rare diseases. The company is advancing its leading pipeline product, a next-generation anti-IgE antibody (LP-003), which is currently in Phase III clinical trials and is preparing for Biologics License Application (BLA) submission in 2025.
Business Information
Target Customers
Industry Categories
Business Model
Funding Timeline
| Round | Date | Amount | Investors |
|---|---|---|---|
| Series C | Jun 03, 2025 | $28.5M | HighLight Capital, Qiming Venture Partners |
Founders
No founder information available.
Investors
HighLight Capital
Venture Capital
Qiming Venture Partners
Venture Capital
Recent Mentions
🇨🇳 #Longbio announced the completion of over RMB 200 million in Series C #financing. This round was co-led by HighLight Capital (HLC) and existing shareholder Qiming Venture Partners. According to the press release, the funds from this round will primarily be used to advance
Similar Startups
Granite Bio
87% matchGranite Bio is focused on developing immunology assets, pioneering a new approach to tackling inflam...
AusperBio
87% matchA clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies.
KiinBio
87% matchKiinBio is a British life sciences startup that has developed a Virtual Scientist Platform for drug ...
CrossBridgeBio
86% matchDeveloping a dual payload platform for non-GLP NHP toxicity data.